Document is current
Any future updates will be listed below
-
Authors
Sampayo-Cordero, Miguel https://orcid.org/0000-0003-1469-3410
Miguel-Huguet, Bernat
Pardo-Mateos, Almudena
Malfettone, Andrea
Pérez-García, José
Llombart-Cussac, Antonio
Cortés, Javier
Moltó-Abad, Marc
Muñoz-Delgado, Cecilia
Pérez-Quintana, Marta
Pérez-López, Jordi
- License Information
-
More Information
Article History
Received: 14 June 2019
Accepted: 13 September 2019
First Online: 21 October 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: We wish to draw the attention of the Editor to the following facts which may be considered as potential conflicts of interest and to significant financial contributions to this works:Miguel Sampayo-Cordero has received consulting and advisor fees from: Nestle Health Science, Laboratorios Leti, Roche and Allergan. In addition, Miguel Sampayo has received research funding fees from Nestle Health Science.Bernat Miguel-Huguet declares no conflict of interest.Almudena Pardo Mateos has been contracted in the past by Shire and by Genzyme.Andrea Malfettone declares no conflict of interest.José Pérez-García has received consulting and advisor fees from: Roche and Eli Lilly.Antonio Llombart-Cussac has received consulting and advisor fees from Roche, GlaxoSmithKline, Novartis, Celgene, Eisai, and AstraZeneca and has stock options, patents and intellectual property from MedSIR.Javier Cortés has received consulting and advisor fees from: Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo and Erytech. In addition, Javier Cortés has received honorarias from: Roche, Novartis, Celgene, Eisai, Pfizer and Samsung. Add more, Javier Cortés has received research funding fees to the institution from Roche. Finally, Javier Cortés has stock options, patents and intellectual property from MedSIR.Marc Moltó-Abad has received research support from Shire; has received fees from Sanofi/Genzyme, Shire and Alexion for participation in their respective registries. In addition, this work used laronidase, a product manufactured by Shire, to evaluate the efficacy of ERT in MPS II patients.Cecilia Muñoz-Delgado as received consulting fees, fees as a speaker, and research support from Shire and Genzyme.Marta Pérez-Quintana as received consulting fees, fees as a speaker, and research support from Shire.Jordi Pérez-López has received consulting fees, fees as a speaker, and research support from Shire.
